MedTrace Logo

Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

NCT01656759 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2016-02-09

Study results available
· View outcomes & findings →

Summary

Applying a fibrin spray, after knee device implantation, will help in reducing patient blood loss and decrease the drop in both hemoglobin and hematocrit levels. Also, with decreased blood loss there should be a reduced need for blood transfusions.

Conditions

Interventions

DRUG

Evicel Fibrin Spray

10cc syringe dose, once at the end of TKA

Sponsors & Collaborators

  • Rush University Medical Center

    lead OTHER

Principal Investigators

  • Brett R Levine, MD · RUMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-12-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01656759 on ClinicalTrials.gov